How MONJUVI was studied

The combination of MONJUVI and lenalidomide was studied in 71 people whose DLBCL came back, got worse, or didn’t respond to treatment. They received this treatment for up to 12 cycles. Then they were given MONJUVI alone.

Doctor and patient

The study measured how many people reached complete or partial remission. It also measured how long they stayed in complete or partial remission.

Complete remission (also known as complete response) is the disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.

Partial remission (also known as partial response) is a decrease (usually at least 50% in DLBCL) in the size of a tumor, or in the extent of cancer in the body, in response to treatment.

How MONJUVI and
lenalidomide may help

Reaching remission

A majority of people treated responded to MONJUVI and lenalidomide.

55% of people (39 out of 71) receiving MONJUVI and lenalidomide reached some form of remission.

  • 37% of people reached complete remission*

  • 18% of people reached partial remission

55%

18%

37%

Bar graph of partial remission and complete remission on MONJUVI Bar graph of partial remission and complete remission on MONJUVI

Every person is unique.

How your condition progresses and how you may respond to MONJUVI depends on your individual circumstances.

Talk to your doctor to learn more about MONJUVI.

*Complete remission (also known as complete response) is the disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.

Partial remission (also known as partial response) is a decrease (usually at least 50% in DLBCL) in the size of a tumor, or in the extent of cancer in the body, in response to treatment.

In this study, an analysis was done to estimate how long people may respond to treatment. This is referred to as duration of response. In the study, there was a 50% probability that patients maintained their response for 22 months.

MEDIAN

DURATION

OF RESPONSE

(Range: 0 to 24 months)

Median duration of response graphic: about 22 months Median duration of response graphic: about 22 months

The median is the middle number in a group of numbers.

These results are based on 39 out of 71 patients in the study.

How is MONJUVI unique?

MONJUVI is not chemotherapy. B cells are part of a healthy person's immune system. They help your body fight infection. In DLBCL, B cells grow out of control, both in size and number. The images below show how MONJUVI works.

Graphic of a cancerous cell, MONJUVI binding to CD19 marker, and immune cell killing cancer cell. Graphic of a cancerous cell, MONJUVI binding to CD19 marker, and immune cell killing cancer cell.

1

Cancerous B cell with CD19 markers.

2

MONJUVI locates and binds
to the CD19 marker on the surface
of cancerous B cells.

3

This binding action triggers
immune cells to kill the cancer cells.

Taking MONJUVI and lenalidomide together may help treat your relapsed or refractory DLBCL. MONJUVI targets the cancer directly and activates your immune system to fight relapsed or refractory DLBCL. MONJUVI can also affect healthy cells.

Learn more about how you will receive MONJUVI and your treatment schedule.

BACK TO TOP